Biomea Fusion (NASDAQ: BMEA)

Last close As at 08/10/2025

USD1.68

−0.17 (−8.94%)

Market capitalisation

USD100m

Biomea Fusion is a US-based clinical-stage biopharmaceutical company focused on the development of novel covalent small molecules for the treatment of metabolic diseases and genetically defined cancers.

Latest Insights

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Franco Valle

    CFO

  • Thomas Butler

    Founder, chairman and CEO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free